Compare

iRhythm/$IRTC

1D1W1M3M6MYTD1Y5YMAX

About iRhythm

iRhythm Holdings Inc is a digital healthcare company that creates trusted solutions that detect, predict, and prevent disease. Its principal business is the design, development, and commercialization of device-based technology to provide ambulatory cardiac monitoring services that it believes allow clinicians to diagnose certain arrhythmias quicker and with greater efficiency than other services that rely on traditional technology. Each Zio System combines an FDA-cleared and CE-marked, wire-free, patch-based, 14-day wearable biosensor that continuously records electrocardiogram (ECG) data with a proprietary, FDA-cleared, CE-marked cloud-based data analytic software to help physicians monitor patients and diagnose arrhythmias.
Ticker
$IRTC
Sector
Health
Primary listing
NASDAQ
Employees
2,400

iRhythm Metrics

BasicAdvanced
$3.2B
-
-$1.18
1.47
-

What the Analysts think about iRhythm

Analyst ratings (Buy, Hold, Sell) for iRhythm stock.
Analyst projections of the future price of iRhythm stock.

Bulls say / Bears say

Third-quarter revenue grew 14.9% year on year, and iRhythm raised its 2026 revenue and adjusted EBITDA margin guidance. This suggests demand for its core Zio Monitor is translating into growth and stronger operating leverage. (GlobeNewswire)
The FDA-cleared third-generation algorithm is expected to cut clinician review time by up to 50% and generate about $100 million in cumulative savings over five years. If delivered, those efficiencies could support further margin gains as volumes grow. (iRhythm)
The completed VitalConnect acquisition gives iRhythm an FDA-cleared mobile cardiac telemetry product and longer-wear monitoring capabilities. The broader portfolio could help it serve more patient and care settings. (iRhythm)
Zio AT revenue was flat in the third quarter, below management’s expectations, as some customers delayed purchases while waiting for the VitalConnect integration. Management expects a further year-on-year decline in Q4, making near-term growth more dependent on the core Zio Monitor. (The Motley Fool)
iRhythm has pushed its planned Zio MCT FDA submission from 2026 into 2027 and is prioritising VitalConnect integration. That delays a key planned product and leaves execution of the combined portfolio as an important near-term test. (The Motley Fool)
Regulatory uncertainty remains: iRhythm says its FDA warning letter remediation is complete but it is still awaiting a follow-up inspection, while dialogue with the DOJ continues. Further regulatory action or prolonged review could distract management and create financial or operating risk. (The Motley Fool)
Data summarised monthly by Lightyear AI. Last updated on 6 Nov 2026.

iRhythm Financial Performance

Revenues and expenses
Income statement
AnnuallyQuarterly
2023
YoY growth
Revenue
Net income
Profit margin

iRhythm Earnings Performance

Company profitability
Earnings per share
AnnuallyQuarterly
2020
2021
2022
2023
2024
Actual
Expected
Surprise

Funds containing iRhythm

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.